Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
14 mai 2024 16h15 HE
|
Vincerx Pharma, Inc.
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a first-in-class small molecule-drug...
Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
26 avr. 2024 00h27 HE
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced the pricing of an underwritten public offering of (i) 6,000,000 shares of its common stock...
Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
25 avr. 2024 16h01 HE
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced a proposed underwritten public offering of shares of its common stock and accompanying...
Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
08 avr. 2024 16h30 HE
|
Vincerx Pharma, Inc.
VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic...
Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
01 avr. 2024 08h00 HE
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...
Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
29 mars 2024 15h20 HE
|
Vincerx Pharma, Inc.
VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM...
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
05 mars 2024 16h31 HE
|
Vincerx Pharma, Inc.
PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through...